- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 99
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 1,622
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Degeneration
- Interventions
- Anecortave Acetate Sterile Suspension (15 mg)
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 50 Years and older
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Retinal Vein Occlusion
- Interventions
- Aflibercept Ophthalmic
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Age Related Macular Degeneration
- Interventions
- aflibercept 2.0 mg
- Drug
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration, Traumatic Optic Neuropathy, Optic Atrophy
- Interventions
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Biological
- Lead sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Naples, Florida
- Conditions
- Age Related Maculopathy, Retinal Degeneration
- Interventions
- Eccentric Viewing Training for Reading
- Procedure
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept, Ranibizumab, Bevacizumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 369,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 1467335, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Levodopa, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Age Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Durham, North Carolina + 1 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more
- Conditions
- Retinitis Pigmentosa, Choroideremia
- Interventions
- RTx-015
- Genetic
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Orange, California • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Mucolipidosis Type IV
- Interventions
- Not listed
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 1 Year to 64 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Scott Raymond
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Proliferative Vitreoretinopathy
- Interventions
- Methotrexate
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Age-Related Macular Degeneration
- Interventions
- KH658
- Drug
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Lemont, Illinois • Memphis, Tennessee
- Conditions
- Retinal Disease, Glaucoma, Optic Nerve Diseases
- Interventions
- Investigational contact OCT system, Investigational noncontact OCT system:
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Usher Syndrome, Retinitis Pigmentosa
- Interventions
- SAR421869
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Age-related Macular Degeneration
- Interventions
- Sildenafil citrate
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-Related Macular Degeneration
- Interventions
- FORESEE HOME
- Device
- Lead sponsor
- Notal Vision Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Toms River, New Jersey
- Conditions
- Macular Edema, Diabetes Mellitus
- Interventions
- Vitamin E
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinopathy of Prematurity
- Interventions
- imaged with i-Cam OCT
- Device
- Lead sponsor
- Siloam Vision
- Industry
- Eligibility
- 4 Weeks and older
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
- Interventions
- Ixo-vec
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more